Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice.

ABSTRACT: Background and Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related mortality and morbidity worldwide. Bevacizumab was approved for the treatment of metastatic colorectal cancer (mCRC) based on favorable benefit-risk assessments from randomized controlled trials, but evidence on its use in the real-world setting is limited. The aim of the current study is to evaluate the outcomes and safety profile of bevacizumab in mCRC in a real-world setting in Romania. Patients and Methods: This was an observational, retrospective, multicentric, cohort study conducted in Romania that included patients with mCRC treated with bevacizumab as part of routine clinical practice. Study endpoints were progression-free survival, overall survival, adverse events, and patterns of

SUBMITTER: Dinu IM 

PROVIDER: S-EPMC9963555 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature